Enhanced vascular permeability in solid tumor involving peroxynitrite and matrix metalloproteinases.
Peroxynitrite (ONOO(-)), which is generated from nitric oxide (NO) and superoxide anion (O(2)(.-)) under pathological conditions, plays an important role in pathophysiological processes. Activation of matrix metalloproteinases (MMPs) contributes to tumor angiogenesis and metastasis. NO mediates the enhanced vascular permeability and retention (EPR) effect in solid tumors, and ONOO(-)activates proMMP to MMP in vitro. In this study, we examined the role of ONOO(-)in the EPR effect in solid tumors and normal tissues as related to MMP activation. Authentic ONOO(-), at 50 nmol or higher concentrations, induced the enhanced vascular permeability in normal dorsal skin of mice. ONOO(-)scavengers ebselen and uric acid significantly suppressed the EPR effect in mouse sarcoma 180 (S-180) tumors. Indirect evidence for formation of ONOO(-)in S-180 and mouse colon adenocarcinoma (C-38) tumors included strong immunostaining for nitrotyrosine in the tumor tissue, predominantly surrounding the tumor vessels. MMP inhibitor BE16627B (66.6 mg / kg i.v., given 2 times) or SI-27 (10 mg / kg i.p., given 2 times) significantly suppressed the ONOO(-)-induced EPR effect in S-180 tumors and in normal skin. Soybean trypsin inhibitor (Kunitz type), broad-spectrum proteinase inhibitor ovomacroglobulin, and bradykinin receptor antagonist HOE 140 also significantly suppressed the ONOO(-)-induced EPR effect in normal skin tissues. These data suggest that ONOO(-)may be involved in and promote the EPR effect in tumors, which could be mediated partly through activation of MMPs and a subsequent proteinase cascade to generate potent vasoactive mediators such as bradykinin.
Wu
J
J
Department of Microbiology, Kumamoto University School of Medicine, Kumamoto 860-0811, Japan.
Akaike
T
T
Hayashida
K
K
Okamoto
T
T
Okuyama
A
A
Maeda
H
H
D000230:Adenocarcinoma / Q000098:blood supply* / Q000201:enzymology; D000818:Animals; D001393:Azoles / Q000494:pharmacology; D001920:Bradykinin / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors / Q000494:pharmacology / Q000502:physiology; D002199:Capillary Permeability / Q000187:drug effects; D017364:Collagenases / Q000378:metabolism; D003110:Colonic Neoplasms / Q000098:blood supply* / Q000201:enzymology; D004305:Dose-Response Relationship, Drug; D004792:Enzyme Precursors / Q000378:metabolism; D016166:Free Radical Scavengers / Q000494:pharmacology; D018093:Gelatinases / Q000378:metabolism; D006168:Guinea Pigs; D054833:Isoindoles; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000096:biosynthesis / Q000378:metabolism*; D020780:Matrix Metalloproteinase 9 / Q000096:biosynthesis / Q000378:metabolism*; D061965:Matrix Metalloproteinase Inhibitors; D008666:Metalloendopeptidases / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D009566:Nitrates / Q000378:metabolism / Q000494:pharmacology / Q000502:physiology*; D009842:Oligopeptides / Q000494:pharmacology; D016566:Organoselenium Compounds / Q000494:pharmacology; D011480:Protease Inhibitors / Q000494:pharmacology; D012510:Sarcoma 180 / Q000098:blood supply* / Q000201:enzymology; D012867:Skin / Q000098:blood supply / Q000201:enzymology; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000096:biosynthesis; D014527:Uric Acid / Q000494:pharmacology
D001393:Azoles; D004792:Enzyme Precursors; D016166:Free Radical Scavengers; D054833:Isoindoles; D061965:Matrix Metalloproteinase Inhibitors; D009566:Nitrates; D009842:Oligopeptides; D016566:Organoselenium Compounds; D011480:Protease Inhibitors; C421267:SI 27; C039642:peroxynitric acid; D014527:Uric Acid; C002744:3-nitrotyrosine; C042986:ebselen; D014443:Tyrosine; C065679:icatibant; D017364:Collagenases; D018093:Gelatinases; D008666:Metalloendopeptidases; C120487:pro-matrix metalloproteinase 9; C069860:progelatinase; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9; D001920:Bradykinin